Compare MGPI & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGPI | NPCE |
|---|---|---|
| Founded | 1941 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.4M | 514.3M |
| IPO Year | 1988 | 2021 |
| Metric | MGPI | NPCE |
|---|---|---|
| Price | $26.27 | $15.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $30.75 | $18.14 |
| AVG Volume (30 Days) | ★ 221.1K | 198.0K |
| Earning Date | 02-25-2026 | 03-03-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $578,855,000.00 | $94,864,000.00 |
| Revenue This Year | N/A | $25.30 |
| Revenue Next Year | N/A | $0.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $21.67 | $7.56 |
| 52 Week High | $35.50 | $18.98 |
| Indicator | MGPI | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 47.94 |
| Support Level | $24.27 | $15.32 |
| Resistance Level | $26.59 | $16.72 |
| Average True Range (ATR) | 0.73 | 0.65 |
| MACD | 0.12 | -0.10 |
| Stochastic Oscillator | 77.54 | 37.11 |
MGP Ingredients Inc is a producer and supplier of premium distilled spirits and specialty wheat protein and starch food ingredients. MGP also produces high-quality industrial alcohol for use in both food and non-food applications. It operates in three segments: Distillery Solutions, Branded Spirits Segment, and Ingredient Solutions. Distillery Solutions provides distillery co-products, such as distillers feed, fuel grade alcohol, and corn oil: and warehouse services, including barrel put away, storage, and retrieval services. It derives its revenue from the Distillery Solutions segment.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.